Novartis Partners on Cardiovascular Therapies
By

By
Novartis has formed a collaboration and option agreement with Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical company, and Ionis’ subsidiary, Akcea Therapeutics, based in Cambridge, Masachusetts, to license two cardiovascular treatments.…

Takeda in Pact for Celiac Disease Therapy
By

By
Takeda Pharmaceutical has entered into an agreement with PvP Biologics, a San Diego-headquartered biopharmaceutical company, for the development of KumaMax, a compound under development for treating celiac disease. KumaMax is…

Pfizer in Antibody-Development Deal
By

By
Pfizer has formed a collaboration with AbCellera Biologics, a privately held biotechnology company headquartered in Vancouver, British Columbia, Canada, to discover and develop therapeutic antibodies against undisclosed membrane protein targets…

Eisai Acquires Global Rights for Weight Management Drug
By

By
Eisai, with its US pharmaceutical subsidiary Eisai Inc., has revised an agreement with Arena Pharmaceuticals, a San Diego-based biopharmaceutical company, and its wholly owned subsidiary, Arena Pharmaceuticals GmbH, so that…

AstraZeneca Acquires Thrombosis Drug Candidate
By

By
AstraZeneca has entered into an agreement with APT Therapeutics, a privately held biopharmaceutical company headquartered in St. Louis, Missouri, to acquire APT Therapeutic’s thrombosis drug candidate, APT102, a human apyrase…

Shire Sells mRNA Therapy Platform to RaNA
By

By
Shire has sold its MRT platform, which is an mRNA-based therapy platform developed by its subsidiaries, to RaNA Therapeutics, a Cambridge, Massachusetts-based company focused on RNA-targeted medicines. Under the agreement,…

Takeda to Acquire Ariad in $5.2-Billion Deal
By

By
Takeda Pharmaceutical has agreed to acquire Ariad Pharmaceuticals, headquartered in Cambridge, Massachusetts, for $24 per share in cash, or an enterprise value of approximately $5.2 billion. The acquisition boosts Takeda’s…

Merrimack in $1.03-Billion Deal to Divest Cancer Drugs
By

By
Merrimack Pharmaceuticals, headquartered in Cambridge, Massachusetts, has agreed to sell two oncology drugs to Ipsen, a pharmaceutical company headquartered in Paris, France, in a transaction valued at up to $1.025…

Merck KGaA in Oncology Pact with Texas University
By

By
EMD Serono, the biopharmaceutical business of Merck KGaA, has formed a three-year strategic collaboration with The University of Texas MD Anderson Cancer Center, located in Houston, Texas, with the aim…

AbbVie Forms Four Oncology, Immunology Pacts
By

By
AbbVie has formed four new collaborations and investments with healthcare innovators to advance early-stage research in key therapeutic areas such as oncology and immunology. One of the oncology collaborations formed…